This year’s European Association of Allergy and Immunology (EAACI) Hybrid Congress was held in-person, in the beautiful historic…

During this symposium, leading experts in paediatric allergy and immunology examined evidence for the immunomodulatory role of human milk oligosaccharides (HMO) in infants with cow’s milk protein allergy (CMPA), and considered the implications for clinical management.

The following highlights spotlight selected abstracts presented at the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress.

The ongoing large-scale screen of non-M41 variants in patients suspected of HMs continues to detect both recurrent and novel non-M41 variants. The patients harbouring non-M41 variants are rare but may be more malignant.

Honing in on urticaria and other mast cell driven diseases, experts at the EAACI Congress 2023 presented a forward-thinking session in one of the most insightful symposia from the hybrid meeting hosted in Hamburg, Germany.

The availability of specific licensed medicines to treat acute HAE attacks and prophylactic options to prevent future episodes is changing the way people with HAE are treated, and is giving them hope for a future free from debilitating HAE attacks.

A captivating session, presented at EHA Congress 2023, on sickle cell disease explored the role of allogeneic stem cell transplantation in this condition, as well as gene therapy and gene editing in treating patients with SCD.

Targeted Therapeutics in CLL and MCL. Applying Emerging BTK Inhibitor Therapy Data to Practice. This infographic was supported by educational grant from Lilly.

This infographic explores the clinical relevance of allergen immunotherapies asthma, hay fever and rhinitis, and the patient benefits observed.